BR112021016171A2 - Combinações de iadademstat para terapia de câncer - Google Patents

Combinações de iadademstat para terapia de câncer Download PDF

Info

Publication number
BR112021016171A2
BR112021016171A2 BR112021016171-6A BR112021016171A BR112021016171A2 BR 112021016171 A2 BR112021016171 A2 BR 112021016171A2 BR 112021016171 A BR112021016171 A BR 112021016171A BR 112021016171 A2 BR112021016171 A2 BR 112021016171A2
Authority
BR
Brazil
Prior art keywords
inhibitor
combination
cancer
use according
iadademstat
Prior art date
Application number
BR112021016171-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Filippo CICERI
Original Assignee
Oryzon Genomics, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics, S.A. filed Critical Oryzon Genomics, S.A.
Publication of BR112021016171A2 publication Critical patent/BR112021016171A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112021016171-6A 2019-03-25 2020-03-25 Combinações de iadademstat para terapia de câncer BR112021016171A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382206 2019-03-25
EP19382206.1 2019-03-25
PCT/EP2020/058362 WO2020193631A1 (en) 2019-03-25 2020-03-25 Combinations of iadademstat for cancer therapy

Publications (1)

Publication Number Publication Date
BR112021016171A2 true BR112021016171A2 (pt) 2021-10-05

Family

ID=66175363

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016171-6A BR112021016171A2 (pt) 2019-03-25 2020-03-25 Combinações de iadademstat para terapia de câncer

Country Status (13)

Country Link
US (1) US20220175698A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946295B1 (cg-RX-API-DMAC7.html)
JP (2) JP7824627B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210142614A (cg-RX-API-DMAC7.html)
CN (2) CN113573702A (cg-RX-API-DMAC7.html)
AU (1) AU2020249493B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016171A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132473A1 (cg-RX-API-DMAC7.html)
IL (1) IL286353A (cg-RX-API-DMAC7.html)
MX (1) MX2021011610A (cg-RX-API-DMAC7.html)
PH (1) PH12021552326A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109025XA (cg-RX-API-DMAC7.html)
WO (1) WO2020193631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913290QA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SI3941466T1 (sl) 2019-03-20 2026-04-30 Oryzon Genomics, S.A. Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US20190256929A1 (en) * 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy

Also Published As

Publication number Publication date
CN113573702A (zh) 2021-10-29
JP7824627B2 (ja) 2026-03-05
SG11202109025XA (en) 2021-09-29
JP2026077769A (ja) 2026-05-13
KR20210142614A (ko) 2021-11-25
AU2020249493A1 (en) 2021-09-16
PH12021552326A1 (en) 2022-06-27
JP2022526525A (ja) 2022-05-25
EP3946295A1 (en) 2022-02-09
CA3132473A1 (en) 2020-10-01
CN121422229A (zh) 2026-01-30
US20220175698A1 (en) 2022-06-09
WO2020193631A1 (en) 2020-10-01
EP3946295B1 (en) 2026-08-05
AU2020249493B2 (en) 2025-08-28
IL286353A (en) 2021-10-31
MX2021011610A (es) 2021-10-13

Similar Documents

Publication Publication Date Title
US11446309B2 (en) Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
JP2019517549A5 (cg-RX-API-DMAC7.html)
JP2026077769A (ja) 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物
US20230080216A1 (en) Compounds for treating tnbc
CA2909160C (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
JP6570512B2 (ja) 新規なStat3阻害剤
TW201914592A (zh) 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2021514975A (ja) サイクリン依存性キナーゼ阻害剤およびbet−ブロモドメイン阻害剤の組合せ
JP2011520846A (ja) 多発性骨髄腫の治療
WO2020233602A1 (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
CN103889409A (zh) N-羟基-4-{2-[3-(n,n-二甲基氨基甲基)苯并呋喃-2-基羰基氨基]乙氧基}苯甲酰胺的给药方案
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
MXPA04006822A (es) Combinaciones que comprenden epotilonas y anti-metabolitos.
RU2833564C2 (ru) Комбинации иададемстата для лечения рака
CN103442708B (zh) 治疗性处理
JP2023501317A5 (cg-RX-API-DMAC7.html)
JP7504106B2 (ja) がんの処置のための組合せ物
CN111565719A (zh) 用于治疗食管癌的crac通道调节剂
CN100553634C (zh) 用于治疗多发性骨髓瘤的埃坡霉素衍生物
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
JPH06505487A (ja) 食道癌の治療用医薬組成物
EP1485090B1 (en) Combinations comprising an epothilone derivative and an imidazotetrazinone
RU2837046C1 (ru) Применение ингибиторов btk при лечении заболеваний
KR20170084328A (ko) 모노클로날 항체의 투여를 위한 병용 요법
CN118436642A (zh) 干扰肿瘤Treg细胞分化的药物及其应用

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]